Severe adverse drug reactions,which appear to be idiosyncratic and unpredictable,are a major issue for drug therapy.Genetic factors or genome polymorphisms contribute to the susceptibility or heterogeneity.More discovery of risk alleles for these severe drug reactions may benefit the prediction of individuals.In this review,we clarify the current status of the genetic polymorphism of pharmacogenetic biomarkers about severe adverse drug reactions in skin and liver from open data sources.